About the Company
we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GH News
Guardant Health: Shield Launch Could Drive Multiple Expansion
GH can prove to the market they have a competitive product in Shield can gain a foothold in the roughly 50m unscreened CRC ...
Blood test shows 83% accuracy for detecting colorectal cancer, study finds
A new screening method for colorectal cancer may be on the horizon. A clinical study showed 83% accuracy for a blood test ...
Buy Rating Affirmed for Guardant Health Amid Strong Shield Test Prospects and Positive ECLIPSE Study Results
Canaccord Genuity analyst Kyle Mikson CFA has reiterated their bullish stance on GH stock, giving a Buy rating today. Kyle Mikson CFA has ...
In large trial, Guardant Health’s blood test detects colon cancer, but less reliably at earliest or precancerous stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
Guardant Health Inc (NASDAQ: GH) Is Down -31.09% So Far This Year: What Will Happen Next?
The trading price of Guardant Health Inc (NASDAQ:GH) closed lower on Tuesday,March 12, closing at $18.64, -1.84% lower than its previous close. In examining the 52-week price action we see that the ...
Promising new blood test could catch colon cancer early, expand screening options
A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading ...
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement ...
GH Jul 2024 10.000 put
The maker of the test, Guardant Health, anticipates an FDA decision this year. PALO ALTO, Calif., March 13, 2024--ECLIPSE study to be published in NEJM shows Shield blood-based screening test detects ...
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources ...
Insiders Buying Advance Auto Parts And 2 Other Stocks
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it ...
Blood test shows 83% accuracy for detecting colorectal cancer in trial
A blood test to screen for colorectal cancer in average-risk individuals without symptoms accurately detected the malignancy ...
Loading the latest forecasts...